IBD治疗护理路径可降低医疗成本并具成本效果:多中心IBD价值研究结果
该多中心研究评估了晚期治疗护理路径(ACP)对炎症性肠病(IBD)患者成本与生活质量的影响,采用成本-效用与成本-效果分析。ACP在六家医院实施,两家同级医院为对照,共纳入1,173例患者。结果显示干预后干预组成本下降而对照组未降,DiD分析显示成本节约-€1933.69,QALYs与疾病控制无变化,ICER提示节约成本且不损害生活质量或疾病控制。
要点
- ACP实施后干预医院人均成本从€23,259.96降至€20,959.76,对照组未降。
- DiD分析显示成本节约-€1933.69,QALYs(0.001)与疾病控制(0.15)无变化。
- ICER提示ACP节约成本且不损害生活质量或疾病控制,具成本效果。
核心结论
- 实施IBD晚期治疗护理路径可降低医疗成本,维持生活质量与疾病控制,且具成本效果。
研究设计与样本
- 成本-效用与成本-效果分析,社会视角,ACP在六家医院实施,两家同级医院为对照。
主要发现
- 干预医院人均成本从基线€23,259.96降至干预期€20,959.76,对照医院从€22,837.93变为€22,191.21。
- DiD分析显示成本节约-€1933.69,QALYs变化0.001,疾病控制变化0.15。
- ICER提示节约成本且不损害生活质量或疾病控制。
关键数值与推荐
- QALYs由EQ-5D-5L推导,疾病控制由IBD-Control问卷评估。
- 计算净货币效益与增量成本效果比(ICER)。
临床怎么用
- 在当前实践中应考虑实施IBD护理路径以降低医疗成本并维持生活质量与疾病控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An advanced therapy care pathway (ACP) for the treatment of patients with IBD can reduce practice variation and improve outcomes. AIMS: This study aimed to estimate the effect of the ACP on costs and quality of life, and to assess the cost-effectiveness of the ACP. METHODS: A cost-utility and cost-effectiveness analysis was conducted from a societal perspective. The ACP was implemented in six hospitals, and two hospitals in the same region served as controls. Costs and quality of life were assessed during a baseline period (December 2020-December 2021) and an intervention period after implementing the ACP (March 2022-March 2023). Quality-adjusted life years (QALYs) were derived from the EQ-5D-5L; disease control from the IBD-Control questionnaire. A difference-in-differences (DiD) analysis was conducted, and the net monetary benefit and incremental cost-effectiveness ratio (ICER) were calculated. RESULTS: In total, 1,173 patients were included (intervention n = 841, control n = 332). Baseline costs per patient were €23,259.96 in the intervention hospitals and €22,837.93 in the control hospitals. During the intervention period, costs decreased to €20,959.76 in intervention hospitals. This reduction was not observed in control hospitals (€22,191.21). The DiD-analysis showed cost savings of -€1933.69; QALYs (0.001) and disease control (0.15) did not change. The ICER indicated cost savings without compromising quality of life or disease control. CONCLUSIONS: The implementation of an ACP for the treatment of patients with IBD reduces costs, maintains quality of life and disease control, and is cost-effective. These results emphasise that the implementation of care pathways in current practices should be considered. TRIAL REGISTRATION NUMBER: NL-OMON21751. Website: Value-based healthcare for Inflammatory Bowel Disease: Improving (cost-) effectiveness.
引用
- Visser EH, Voshaar MAO, van Linschoten RCA, et al. A Care Pathway for the Treatment of IBD Reduces Healthcare Costs and Is Cost-Effective: Results of the Multicentre IBD Value Study. Aliment Pharmacol Ther. 2026. PMID: 42023738. doi:10.1111/apt.70690
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。